Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (BMY) has entered into a strategic license agreement with Tubulis to develop differentiated antibody-drug conjugates (ADCs) for cancer treatment. BMY will pay Tubulis an upfront fee of $22.75 million, with potential milestone payments exceeding $1 billion and tiered royalties on net sales. This partnership allows BMY access to Tubulis’ proprietary P5 conjugation and Tubutecan platforms, enhancing their capability in ADC development. The agreement highlights BMY's focus on oncology and the therapeutic potential of ADCs, addressing the need for innovative cancer treatments. Tubulis aims to leverage its technologies to create ADCs that reduce unwanted side effects while effectively delivering therapies to solid tumors.
The U.S. FDA has accepted the supplemental Biologics License Application (sBLA) for Bristol Myers Squibb (NYSE:BMY) and 2seventy bio's Abecma (idecabtagene vicleucel), with a target action date set for December 16, 2023. This application is based on promising interim results from the Phase 3 KarMMa-3 study, which demonstrated a significant reduction in disease progression or death for patients with relapsed and refractory multiple myeloma compared to standard treatments. Additionally, the European Medicines Agency validated a Type II variation application for Abecma, and Japan's Ministry of Health accepted the supplemental New Drug Application. These developments highlight the commitment to enhance treatment options for multiple myeloma patients.
Bristol Myers Squibb (NYSE: BMY) has expanded its collaboration with Foundation Medicine to develop the FoundationOne CDx as a companion diagnostic for its investigational tyrosine kinase inhibitor, repotrectinib. This drug is currently under evaluation in the TRIDENT-1 Phase 1/2 trial for patients with ROS1+ non-small cell lung cancer (NSCLC) and NTRK+ solid tumors. If successful, the FoundationOne CDx will help identify suitable patients for treatment with repotrectinib. Foundation Medicine leads in the U.S. with approximately 60% of all companion diagnostic approvals for next-generation sequencing (NGS) testing, enhancing personalized treatment options.
Bristol Myers Squibb has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Breyanzi, aimed at treating adult patients with diffuse large B-cell lymphoma and related conditions who relapse within 12 months after first-line therapy. This endorsement is based on the pivotal Phase 3 TRANSFORM study results, which showcased Breyanzi's efficacy as a second-line treatment compared to conventional methods. The European Commission's final decision is expected within two months. This milestone underscores a new potential standard of care in a critical unmet need for many patients.
Bristol Myers Squibb (BMY) reported three-year follow-up results from the Phase 3 CheckMate -816 trial at ELCC 2023, highlighting significant clinical benefits of neoadjuvant Opdivo (nivolumab) combined with chemotherapy in non-small cell lung cancer (NSCLC). The combination therapy reduced the risk of disease recurrence, progression, or death by 32%, achieving a 57% event-free survival (EFS) rate compared to 43% with chemotherapy alone. Time to distant metastasis or death was also improved, with rates of 71% vs. 50%. Although overall survival data remains immature, a favorable trend was observed, with 78% of patients alive at three years versus 64% with chemotherapy.
Bristol Myers Squibb (NYSE:BMY) announced the European Commission's approval of Sotyktu (deucravacitinib), a first-in-class oral therapy for moderate-to-severe plaque psoriasis. The approval is based on pivotal Phase 3 trials (POETYK PSO-1 and POETYK PSO-2), which demonstrated Sotyktu's superior efficacy over both placebo and Otezla at 16 and 24 weeks, with sustained responses at 52 weeks. Notably, the therapy presents a favorable safety profile. With approximately 14 million people affected by psoriasis in Europe, Sotyktu addresses an urgent need for accessible and effective treatments in this patient population.
CHARM Therapeutics has announced a strategic collaboration with Bristol Myers Squibb (BMY) to utilize its DragonFold deep learning platform for discovering and optimizing compounds against selected targets. CHARM will lead early discovery efforts, while BMY retains the option to license developed compounds. The agreement includes an upfront payment and potential future payments, which enhance CHARM's financial runway. This collaboration aims to accelerate the development of new medicines addressing difficult-to-target diseases, reinforcing BMY's commitment to innovative treatments.
Bristol Myers Squibb (NYSE: BMY) will report its first quarter 2023 financial results on April 27, 2023. The company will hold a conference call at 8:00 a.m. ET to discuss these results, answering questions from investors and analysts. A live webcast will be accessible at http://investor.bms.com. Participants can join by dialing the U.S. toll-free number 888-300-3045 or the international number +1 646-568-1027 (conference code: 3734085). A replay will be available for listening shortly after the call, running until May 11, 2023.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.57 per share on its common stock, payable on May 1, 2023, to shareholders of record by April 10, 2023. Additionally, a dividend of $0.50 per share on its $2.00 convertible preferred stock is set for June 1, 2023, payable to stockholders by May 2, 2023. This reflects the company's commitment to returning value to its shareholders while pursuing its mission to develop innovative medicines for serious diseases.
Viz.ai has entered into a multi-year partnership with Bristol Myers Squibb (BMY) to implement an AI algorithm designed to detect and triage patients for hypertrophic cardiomyopathy (HCM). The AI algorithm, which is under FDA review following a de novo classification request, aims to streamline the identification process for patients who may be at risk. HCM affects millions globally, and timely diagnosis can significantly improve outcomes. The collaboration will enhance capabilities within the Viz.ai Cardio Suite, which is currently utilized by around 1,300 U.S. hospitals.